Division of Bayer AG
Latest From Medrad Inc.
A year after Boston Sci bought Bayer's interventional unit, Medrad, the company says it has received a 510(k) clearance for its ZelanteDVT catheter to be used with its AngioJet Ultra Console to treat deep vein thrombosis as mechanical – rather than drug – DVT treatments are gaining more attention.
Improving the patient’s QoL and preventing disease progression, and with it the threat of critical limb ischemia and amputation, dominate peripheral artery disease management, but emerging technologies and the aging population are set to boost a percutaneous transluminal angioplasty market that is already worth $730 million in the US alone.
After years of rumors that it wanted to get out of the diabetes care business, Bayer announced a $1.15 billion sale of that unit to Panasonic Healthcare Holdings, another step away from the medical device market.
Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
- Monitoring Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Bayer AG
- Senior Management
- Contact Info
Phone: (724) 940-6800
100 Global View Dr.
Warrendale, PA 15086
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.